Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
The private group taps DualityBio for an EGFR x HER3 ADC.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
